Log in

OTCMKTS:IMLFF - InMed Pharmaceuticals Stock Price, Forecast & News

+0.02 (+12.58 %)
(As of 12/10/2019 05:24 AM ET)
Today's Range
Now: $0.21
50-Day Range
MA: $0.20
52-Week Range
Now: $0.21
Volume805,200 shs
Average Volume335,294 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
InMed Pharmaceuticals Inc., a pre-clinical stage biopharmaceutical company, researches and develops cannabinoid-based therapies. The company's lead product is INM-750, a topical cannabinoid product candidate to treat epidermolysis bullosa. The company is also involved in developing INM-085, a cannabinoid-based topical therapy for glaucoma; and INM-405 for the treatment of orofacial pain. In addition, it engages in the development of drugs for the treatment of various diseases, including dermatology, ocular, pain, inflammation, cancer, and other disease areas. It has an agreement with Pharmaseed Ltd to develop a final formulation for INM-750; and work on IND-enabling pharmacology and toxicology studies. The company also has research agreement with the National Research Council of Canada in for biofermentation development and scale-up processes for cannabinoid biosynthesis in E.coli. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is based in Vancouver, Canada.

Industry, Sector and Symbol

Industry Biotechnology
SectorHealth Technology
Phone(604) 669-7207



Sales & Book Value

Annual SalesN/A



Next Earnings DateN/A
OptionableNot Optionable

Receive IMLFF News and Ratings via Email

Sign-up to receive the latest news and ratings for IMLFF and its competitors with MarketBeat's FREE daily newsletter.

InMed Pharmaceuticals (OTCMKTS:IMLFF) Frequently Asked Questions

What is InMed Pharmaceuticals' stock symbol?

InMed Pharmaceuticals trades on the OTCMKTS under the ticker symbol "IMLFF."

Has InMed Pharmaceuticals been receiving favorable news coverage?

Media coverage about IMLFF stock has been trending somewhat negative this week, according to InfoTrie. The research firm rates the sentiment of media coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. InMed Pharmaceuticals earned a news sentiment score of -1.2 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the stock's share price in the next few days. View News Stories for InMed Pharmaceuticals.

Who are some of InMed Pharmaceuticals' key competitors?

What other stocks do shareholders of InMed Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other InMed Pharmaceuticals investors own include Aurora Cannabis (ACBFF), Canopy Growth (CGC), Aurora Cannabis (ACB), Zynerba Pharmaceuticals (ZYNE), 22nd Century Group (XXII), Terra Tech (TRTC), GB Sciences (GBLX), Cronos Group (CRON), Insmed (INSM) and Emerald Health Therapeutics (EMHTF).

Who are InMed Pharmaceuticals' key executives?

InMed Pharmaceuticals' management team includes the folowing people:
  • Mr. Eric A. Adams, Pres, CEO & Director (Age 56)
  • Mr. Jeffrey M. Charpentier, CFO & Corp. Sec.
  • Ms. Alexandra D. J. Mancini, Sr. VP of Clinical & Regulatory Affairs
  • Mr. Joshua Blacher, Chief Bus. Officer (Age 46)
  • Dr. Eric C. Hsu, Sr. VP of Preclinical R&D

How do I buy shares of InMed Pharmaceuticals?

Shares of IMLFF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is InMed Pharmaceuticals' stock price today?

One share of IMLFF stock can currently be purchased for approximately $0.21.

What is InMed Pharmaceuticals' official website?

The official website for InMed Pharmaceuticals is http://www.inmedpharma.com/.

How can I contact InMed Pharmaceuticals?

The company can be reached via phone at (604) 669-7207.

MarketBeat Community Rating for InMed Pharmaceuticals (OTCMKTS IMLFF)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  97 (Vote Outperform)
Underperform Votes:  65 (Vote Underperform)
Total Votes:  162
MarketBeat's community ratings are surveys of what our community members think about InMed Pharmaceuticals and other stocks. Vote "Outperform" if you believe IMLFF will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IMLFF will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/10/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel